Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04445519 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

691

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: NCX 470 0.065% (initial phase of trial)
DRUG: Latanoprost 0.005% (initial phase of trial)
DRUG: NCX 470 0.1% (initial phase of trial)
DRUG: NCX 470 0.1% (remainder of trial)
DRUG: Latanoprost 0.005% (remainder of trial)

Sponsor

Nicox Ophthalmics, Inc.